Get the Stockscreener App
0.7243
65.37%
0.2863
After Hours:
.66
-0.0643
-8.88%
Cue Biopharma Inc stock is traded at $0.7243, with a volume of 65.64M.
It is up +65.37% in the last 24 hours and up +155.30% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.438
Open:
$0.42
24h Volume:
65.64M
Relative Volume:
8.28
Market Cap:
$70.74M
Revenue:
$27.47M
Net Income/Loss:
$-26.60M
P/E Ratio:
-2.3111
EPS:
-0.3134
Net Cash Flow:
$-21.86M
1W Performance:
+164.54%
1M Performance:
+155.30%
6M Performance:
-7.73%
1Y Performance:
-9.46%
1-Day Range:
$0.42
$0.74
1-Week Range:
$0.21
$0.74
52-Week Range:
$0.1657
$1.03
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7243 | 42.78M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Cue Biopharma to present preclinical data on CUE-401 at AAI meeting - Investing.com
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - The Manila Times
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
Cue Biopharma Inc stock (US22966J1060): Does its Immuno-STAT platform deliver the T-cell breakthroug - AD HOC NEWS
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
Cue Biopharma, Inc. Files Form 8-K with SEC Detailing Company and Stock Information (April 13, 2026) 30 - Minichart
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Shareholders Approve Reverse Stock Split Flexibility - TipRanks
[8-K] Cue Biopharma, Inc. Reports Material Event - Stock Titan
Cue Biopharma receives $7.5M milestone payment from Boehringer Ingelheim - MSN
Cue Biopharma : CUE - 24/7 Wall St.
Exit Recap: Can Cue Biopharma Inc be recession proofCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cue Biopharma (CUE) SVP and counsel receives 200,000 stock options - Stock Titan
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Executive at Cue Biopharma (CUE) granted 100K stock options - Stock Titan
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory DiseasesSlideshow (NASDAQ:CUE) 2026-04-09 - Seeking Alpha
Milestone under Cue and Boehringer Ingelheim collaboration - BioWorld News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - Bitget
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim By Investing.com - Investing.com Australia
Boehringer pays Cue Biopharma $7.5M to progress lead autoimmune asset - The Pharma Letter
Cue Biopharma (CUE) Achieves Preclinical Milestone with Boehring - GuruFocus
Cue Biopharma to receive $7.5 million preclinical milestone payment from Boehringer Ingelheim collaboration and license agreement - marketscreener.com
Cue Biopharma To Receive $7.5 Million Preclinical Milestone Payment From Boehringer Ingelheim Collaboration And License Agreement - TradingView
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim - Investing.com
A drug partner just triggered a $7.5M payout for Cue Biopharma - Stock Titan
Cue Biopharma R&D Day: CUE-401 IND Filing Targeted for Q2, Phase 1 Data Expected Late 2026 - Defense World
CUE: CUE-401 is set for phase I trials, backed by strong preclinical data and robust partnership funding - TradingView — Track All Markets
Cue Biopharma, Inc. Files Form 8-K SEC Report for April 2026 – Company Details, Stock Information, and Executive Signature - Minichart
Cue Biopharma says preclinical milestone triggers $7.5 mln payment under Boehringer deal - marketscreener.com
Cue Biopharma Says Preclinical Milestone Triggers $7.5 Mln Payment Under Boehringer Deal - TradingView — Track All Markets
Cue Biopharma Reaches Key Preclinical Milestone With Boehringer - TipRanks
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim - Investing.com
Cue Biopharma to receive $7.5M preclinical milestone payment from Boehringer Ingelheim - TradingView — Track All Markets
$7.5M Boehringer milestone advances Cue Biopharma (CUE) B cell program - Stock Titan
CUE Should I Buy - Intellectia AI
CUE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
CUE News & Events - Intellectia AI
CUE.O Forecast — Price Prediction for 2026. Should I Buy CUE.O? - Intellectia AI
CUE.O Technical Analysis & Stock Price Forecast - Intellectia AI
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
IPO Launch: Is Cue Biopharma Inc benefiting from interest rate changesWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cue Biopharma Appoints Lucinda Warren Interim CEO - citybiz
Cue Biopharma names Lucinda Warren interim CEO By Investing.com - Investing.com Australia
Cue Biopharma CEO Resignation Leads to 8% Stock Drop - Intellectia AI
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):